UNASSIGNED: The database included all adults with the code K78 (ICPC-2 code for AF) who received clinical care in Northern Portugal\'s Primary Health Care between January 2016 and December 2018 and were dispensed the same NOAC at the pharmacy.
UNASSIGNED: The results indicate that 10.2% of AF patients on NOAC anticoagulation experienced a stroke. Furthermore, patients treated with apixaban and dabigatran had higher odds of experiencing a stroke compared to those treated with rivaroxaban. Among patients with the same age, gender, and CHA2DS2Vasc Score, apixaban was significantly associated with a higher likelihood of thrombotic events than rivaroxaban.
UNASSIGNED: These results have not been previously reported in studies with real-world data; therefore, a more detailed analysis should be conducted to enhance the validity of these findings.
该数据库包括代码为K78(AF的ICPC-2代码)的所有成年人,他们在2016年1月至2018年12月期间在葡萄牙北部的初级卫生保健机构接受了临床护理,并在药房分配了相同的NOAC。
■结果表明,接受NOAC抗凝治疗的房颤患者中,有10.2%出现了中风。此外,与利伐沙班相比,接受阿哌沙班和达比加群治疗的患者发生卒中的几率更高.在相同年龄的患者中,性别,和CHA2DS2Vasc评分,与利伐沙班相比,阿哌沙班与更高的血栓事件发生可能性显著相关.
■这些结果以前没有在现实世界数据的研究中报道过;因此,应该进行更详细的分析,以提高这些发现的有效性。